News By Tag
News By Place
Healthcare, Regulatory and Reimbursement Landscape – Turkey
The report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.
The new report* explains that Turkey’s current economic woes are presenting a challenge to the country’s healthcare system. Turkish government procedures were successful in preventing the 2009 recession from becoming a full-blown depression, however, November 2010-September 2011 saw the value of Turkish Lira fall by 25%. This resulted in the Lira representing the world's worst performing emerging market currency during this period.
Turkey suffers from a growing prevalence of non-communicable and chronic conditions such as cardiovascular disease and cancer due to increasingly sedentary lifestyles, and an elderly population that has increased to more than 10% of the population. With unemployment in 2011 at 9.9%, the national health insurance programs of Turkey will be heavily burdened as increasing healthcare facilities are demanded by a population that is less able to afford them.
In Turkey, the Social Security Institution (Sosyal Guvenlik Kurumu, SGK) runs the new healthcare reimbursement system and reimburses approximately 80% of all drug purchases. In January 2011, 61.2 million (83%) of the population was covered under SGK insurance. SGK provides long-term benefits such as old-age pensions, invalidity insurance, invalidity pensions and marriage benefits, and short-term benefits such as workers compensation and maternity leave.
For Sample Pages, please click or add the below link to your browser:
However, the private health insurance industry is also well developed in Turkey. Using private insurance typically results in better quality health service in the country, and thus is very popular for those who can afford it. High private healthcare expenditure in private hospitals, which are more plentiful than public facilities, affects patient affordability and makes for a lower coverage of services in public health insurance.
In 2010, Turkey’s pharmaceutical market size was approximately US$9.8 billion, and was the sixth largest in Europe. It has qpspu an estimated Compound Annual Growth Rate (CAGR) of 6.1% from 2005 and looks to reach US$21.6 billion by 2020.
This report is an essential source of information and analysis on Turkey’s healthcare, regulatory and reimbursement landscape. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For further details, please click or add the below link to your browser:
Visit our report store:
For more details contact:pressreleases@
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782